Why Fragmentation Is a Major Risk in Radiopharmaceutical Development
Radiopharmaceutical development brings together some of the most specialized capabilities in oncology research. A single program can require radiochemistry, isotope sourcing, cell-based validation, in vivo model ...
Champions Oncology blog
Trends in Oncology
Join our Trends in Oncology Blog to learn more about upcoming industry topics, educational information about Champions' products, and more!
Why Fragmentation Is a Major Risk in Radiopharmaceutical Development
Radiopharmaceutical development brings together some of the most specialized capabilities in oncology research. A single program can require radiochemistry, isotope sourcing, cell-based validation, in vivo model ...
Subscribe to our blog
New articles on preclinical oncology, delivered to your inbox.
A KRAS mutation is not a strategy: Why allele, co-mutation, and tumor type matter
The next KRAS battleground: modelling resistance before the clinic
Why Benchmarking is Now Essential in KRAS Drug Development
KRAS Has Entered a New Era. Why Your Preclinical Strategy Must Change Now
Daraxonrasib Is Rewriting the Standard of Care. Here's Why Preclinical Benchmarking Matters Now
Scaling Chem-Seq and Functional-Seq to Decode Drug and Genetic Perturbations in Patient-Derived Organoids
How Preclinical PDX Studies Help Guide PSMA Radioligand Development
How to Use PDX Models to Advance Folate Receptor-Alpha ADC Development in Ovarian Cancer